Targeting isoforms p110β and p110δ via RNAi could reduce AKT activation through IGF-I or insulin, indicating that both PI3K isoforms contributing to the upregulation of IGF-1R or IR in AML cells and improving the sensitivity of tumor cells to chemotherapeutical drugs. The gene discussed is IGF1R; the disease is neoplasm.